tbuckley/cabot-search huggingface dataset:
A retrospective risk assessment of patients (pts) with high grade upper (UE) and lower extremity (LE) sarcoma: Predictors of survival.
Authors: Jeffrey Kneisl, Anthony Joseph Crimaldi, James Thomas Symanowski, Will Ahrens, Joshua Patt, Bradley McCall, Michael Bates, Chad Ferguson, Michael B. Livingston, Edward S. Kim
Journal: Journal of Clinical Oncology (2013)

e21504 Background: Patient outcomes of high grade extremity soft tissue sarcomas (STS) are dependent upon grade and size of the primary tumor and extent of surgical resection. Poorer overall survival (OS) has been associated with specific anatomic sites (e.g. head and neck, retroperitoneum) but OS has not been evaluated for UE vs LE. We investigated the relationship of tumor size and anatomic sites with OS in our pts with high grade extremity STS. Methods: A retrospective review of all pts diagnosed with a high grade STS of the UE and LE was performed from 1992-2010 via an IRB approved protocol at Levine Cancer Institute. Pts were included if they had sufficient medical records, limb-sparing surgery, age greater than 18 years, no stage IV disease. All cases were centrally reviewed by a single pathologist. Overall survival was analyzed with Cox proportional hazards models and tumor size was analyzed using ANOVA techniques. Results: 93 pts were identified. 61 pts had LE sarcomas and 32 had UE. Demographics: 52% male, 67% Caucasian, 60% &gt;50 years of age. Disease characteristics included 88% deep and 66% &gt;5cm STS. 13% of pts received chemotherapy and 86% received radiation therapy, consistent with NCCN guidelines and institutional protocol. Median baseline tumor size was 7.0 cm with a range of 1.7-40 cm. LE STS were generally larger than UE; medians 8.5 cm (range 1.7-40 cm) vs 5.0 cm (range 2.0-17 cm), p=0.005. When analyzed quantitatively, larger tumor size correlated with an increased risk of death (p=0.001). 28 total deaths occurred (0.3-5.4 yrs). Death rates were 27.9% (17 deaths) with LE STS vs 34.4% (11 deaths) with UE. LE disease had an overall reduced risk of death (HR=0.543). Pts with tumors &gt;5cm had an increased risk of death (HR=3.235 overall) for both LE (HR=3.042) and UE (HR=3.453) sarcomas. Conclusions: To our knowledge, this is the largest reported cohort of high grade STS that stratified on upper and lower extremities. Larger size was associated with higher risk of death. Additionally, we observed a higher risk of death in patients with UE sarcomas vs. LE sarcomas. Strong consideration should be given to UE vs. LE STS when assessing risk and treatment.
HIGH ATRIAL ECTOPY IN STROKE: AN INDEPENDENT RISK FACTOR?
Authors: Anoop Ninan Koshy, Jithin Sajeev, Kevin Rajakariar, Esther Briganti, Peter Andrew, Mark Zureik, Edward Quine, Shane Parfrey, Prasanna Venkataraman, Louise Roberts, Andrew W. Teh
Journal: Journal of the American College of Cardiology (2017)
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Authors: Chia-Chi Lin, Chih-Hung Hsu, Kai-Yuan Tzen, Jason C. Cheng, Jang-Ming Lee, Hsiu-Po Wang, Pei-Ming Huang, Feng-Ming Hsu, Wei-Wu Chen, Ta-Chen Huang, Ann-Lii Cheng
Journal: Journal of Clinical Oncology (2012)

e14576 Background: To determine if fluorodeoxyglucose positron emission tomography (FDG-PET) could differentiate between responding and non-responding locally advanced esophageal squamous cell carcinoma (ESCC) early in the course of neoadjuvant chemoradiotherapy (CRT). Methods: Patients (pts) with T3 or N1M0-1a (AJCC, 6th Ed) ESCC first received a 21-D cycle of induction chemo (paclitaxel 70 mg/m 2 D 1, 8; cisplatin 30 mg/m 2 D 1, 8; fluorouracil 2000 and leucovorin 300 mg/m 2 24-hr D 1, 8). This was followed by concurrent CRT (paclitaxel 35 mg/m 2 1-hr D 1, 4 /wk, cisplatin 15 mg/m 2 1-hr D 2, 5/wk, and radiotherapy 2 Gy D 1-5 /wk) (Lin CC, et al. Ann Oncol 18:93,2007). When the accumulated radiation dose reached 40 Gy, the feasibility of esophagectomy was evaluated. In pts for whom esophagectomy was not feasible, concurrent CRT was continued to a dose of ≥60 Gy. Serial FDG-PETs were performed before and 14 days after start of induction chemo. Pathologic response (PR) was defined as no or microscopic residual disease. PET response was measured using the standardized uptake value (SUV). Receiver operating characteristic (ROC) analysis was used to evaluate the ability of SUV in distinguishing between PR and non-PR. Results: Of 65 pts (M:F = 60:5, median age 55, range 39-71) with locally advanced (M0:M1a = 58:7) ESCC enrolled from March 2008 to December 2011, 40 pts underwent esophagectomy and 26 pts were pathologic responders. The median SUV decrease 14 days after the start of therapy was 75.8% for pathologic responders and 30.1% for non-responders (p &lt;0.05). In ROC analysis, the area under the curve was 0.70 (95% CI = 0.55-0.86). Using a 35% SUV decrease cutoff value, PET correctly identified 24 of 26 responders (sensitivity 92%) and 8 of 14 non-responders (specificity 57%). The corresponding positive and negative predictive values were 80% and 80%, respectively. Conclusions: A 35% SUV decrease 14 days after the start of induction chemo is significantly associated with PR, but its accuracy in detecting non-responders is too low to justify the clinical use of FDG-PET for early discontinuation of neoadjuvant CRT in pts with locally advanced ESCC.
Survival outcome of small bowel adenocarcinoma (SBA) in the last 12 years: Meta-analysis.
Authors: Tannaz Armaghany, Runhua Shi, Joseph Ryan Shows, Glenn Morris Mills
Journal: Journal of Clinical Oncology (2012)

e14667 Background: Due to rarity, management of SBA is currently controversial. Despite results from several single institutional studies showing no survival benefit with adjuvant chemotherapy, data extrapolated from established colorectal cancer studies are commonly used to manage this cancer. Here we report results of a meta-analysis on data from 14 retrospective studies published in English between years 2000 and 2011. Methods: PubMed database was searched using relevant keywords. Patients with SBA were included. Studies involving ampulary, periampulary and ileocecal valve tumors were excluded. The combined location and stage distribution were adjusted by sample size of each study. Primary outcome for the magnitude of benefit analysis were OS. Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted. A random-effect model according to the method of DerSimonian and Laird was used; a heterogeneity test was used. The effect of adjuvant chemotherapy and/or radiation treatment after curative surgery was evaluated. Effect of stage, grade, and positive lymph node ratio was also evaluated. Results: With available information within 14 studies, mean age of patients was 59.3(95% CI: 56.4 and 62.1). Duodenum was the most common site of primary tumor followed by the jejunum, ileum and not specified sites (59.27%, 23.49%, 11.42%, and 3.03%), respectively. Overall median survival was 17.2 months (95% CI: 13.9 and 20.5). Adjuvant treatment vs. non adjuvant treatment showed a HR of 1.17 (95% CI: 0.71-1.93) that was not statistically significant. HR for low grade vs. high grade tumors was 3.90 (95% CI: 2.15- 7.06). HR for stage was 3.09 (95% CI: 0.89-10.67, p=0.07) comparing high stage with low stage which suggested a marginally statistically significant effect. HR for positive lymph node ratio (LNR) was 4.63 (95% CI: 2.67-8.03). Conclusions: Our meta-analysis suggests adjuvant treatment after cancer directed curative intent surgery does not improve overall survival compared to observation in SBA. Grade of tumor and positive LNR are significant predicators of overall survival whereas stage has marginally significant effect on survival. Future trials investigating new or innovative adjuvant therapy in SBA are needed.
Pivotal Role of FoxO3 and mTORC1 in the Opposite Effects of SDF-1 and TGF-β on Cell Cycle Progression in CD34+ Stem/Progenitor Cells.
Authors: Aurelie Chabanon, Christophe Desterke, Emilie Rodenburger, Denis Clay, Bernadette Guerton, Laetitia Boutin, Olivier Pierre-Louis, Claude Capron, Annelise Bennaceur-Griscelli, Georges Uzan, Lucile Abecassis, Marie-Francoise Bourgeade, Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdiles
Journal: Blood (2007)
Infographics for student assessment: more than meets the eye
Authors: David H Saunders, Andrew Horrell, Andrew Murray
Journal: British Journal of Sports Medicine (2017)

Infographics are attracting attention as a mechanism for conveying health messages to the general population and healthcare professionals.1 Infographics are also appearing within traditional scientific publications as a form of a ‘visual abstract’ to summarise findings,2 or as a stand-alone publication.3 This suggests that students as well as professionals1 should be aware of these forms of visual communication. Therefore, it seems logical to incorporate infographics within academic courses where they could have a range of teaching, learning and assessment roles. Producing an infographic may be an effective way of helping students appreciate their value.

This editorial describes how production of an infographic was used as part of an assessment task on a sport nutrition course delivered to sport and exercise science students, and seeks to raise awareness of their use in academic courses.

It is important that students in the sport and exercise sciences develop the ability to communicate their knowledge effectively. This includes scientific audiences and athletes and patients, as well as …
INITIAL RESULTS AND LONG-TERM FOLLOW-UP OF PERCUTANEOUS MITRAL VALVULOPLASTY IN PATIENTS WITH PULMONARY HYPERTENSION
Authors: Rafael A. Meneguz-Moreno, Jose de Ribamar Costa, Auristela Ramos, Nisia Gomes, Zilda Meneghelo, Alfredo Ferreira Neto, Dimytri Siqueira, Sergio Braga, Cesar Esteves, Amanda Sousa, Alexandre Abizaid
Journal: Journal of the American College of Cardiology (2017)
Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners.
Authors: Vincent Channing Tam, Scott R. Berry, Tina Hsu, Scott A. North, Alan John Neville, Kelvin K. Chan, Sunil Verma
Journal: Journal of Clinical Oncology (2012)

e16558 Background: Deficiencies in undergraduate (UG) oncology education have been documented and there is a lack of data on the quality and quantity of oncology education in postgraduate (PG) family medicine (FM) and internal medicine (IM) training programs. Methods: A self-administered web-survey was created to obtain information regarding the current oncology curriculum at medical schools and PG FM and IM training programs. Survey requests were sent to educators (undergraduate medical education curriculum committee members (UMECCM), family medicine (FMPD) and internal medicine program directors (IMPD), oncologists) and learners (final year medical students (MS), family medicine (FMR) and internal medicine residents (IMR)) at all 17 of Canada’s medical schools. Results: 159 of 961 educators (19 UMECCM, 7 FMPD, 10 IMPD, 54 medical oncologists, 67 radiation oncologists and 2 hematologic oncologists) and 518 of 1966 learners (342 MS, 95 FMR and 81 IMR) completed the survey. Overall response rate was 23% (educators 17%, learners 26%). Responses were received from at least one educator or learner from all 17 medical schools. The amount of oncology education was thought to be inadequate in their respective programs by 58% UMECCM, 57% FMPD and 50% IMPD. 82% of oncologists believed that oncology education was inadequate in their UG and PG FM and IM programs. For learners, oncology education was thought to be inadequate in their respective programs by 67% MS, 86% FMR and 63% IMR. Of 10 different categories of medical illness all groups agreed that their trainees were least adequately prepared to manage cancer. A standard set of oncology objectives was thought to be useful for UG learners by 59% of respondents and 61% for PG learners. The 3 topics considered most important as core competencies in oncology for both UG and PG learners are: cancer diagnosis, breaking bad news and cancer screening. Conclusions: Oncology education at the UG medical and PG FM and IM levels are currently thought to be inadequate by a majority of educators and learners. Developing a standard set of oncology objectives focusing on topics believed to be most important by educators may improve the quality of oncology education for learners.
Association of epidemiologic exposures with complete remission after therapy in acute myeloid leukemia (AML).
Authors: Laura Elizabeth Finn, Lisa Ostrosky Sproat, Michael Heckman, Riccardo Valdez, Nancy N. Diehl, Liuyan Jiang, Rhett Ketterling, James M. Foran
Journal: Journal of Clinical Oncology (2014)

7092 Background: Complete remission (CR) after induction chemotherapy is a vital prognosticator in AML. Age and comorbidities impact response and tolerance to AML induction chemotherapy however the influence of epidemiologic exposures is unknown. We therefore evaluated relevant exposures in a cohort of 295 consecutive AML patients with confirmed central cytogenetics analysis diagnosed and treated at Mayo Clinic Florida and Arizona since 1995. Methods: Documented patient exposures extracted systematically from a centralized EMR included prior chemotherapy/radiation (therapy AML, tAML) or hematologic malignancy (secondary AML), medications, and prior solid organ transplantation. Patients receiving induction chemotherapy and responses to therapy were identified. The association of epidemiologic exposures with CR after induction chemotherapy was evaluated by multivariable analysis using logistic regression models. Results: 188 patients received induction chemotherapy. Age was not an independent predictor of CR. tAML after breast cancer was independently and significantly associated with achieving CR after therapy, as was statin use. In contrast prior solid organ transplant, farm habitat, tobacco use, and poor risk cytogenetics were associated with decreased CR. Conclusions: Some epidemiologic exposures impact CR after AML induction chemotherapy in AML. This supports a link between exposures and outcome after therapy with curative intent. This requires validation in a prospective therapeutic clinical trial. CR after induction chemotherapy (OR, CI 95%). Variable N Single Variable P Multivariable P Age > 60 121 1.00 (0.54; 1.84) 1.00 0.71 (0.37; 1.37) 0.31 Statins 38 2.87 (1.23; 6.67) 0.014 2.89 (1.22; 6.85) 0.016 Farm habitat 9 0.30 (0.07; 1.24) 0.095 0.23 (0.05; 1.07) 0.062 Solid organ Tx 7 0.10 (0.01; 0.83) 0.033 0.10 (0.01; 0.84) 0.035 Tobacco 104 0.66 (0.36; 1.19) 0.17 0.57 (0.31; 1.07) 0.079 Poor cytogenetics 63 0.31 (0.08; 1.22) 0.13 0.28 (0.07; 1.10) 0.085 tAML 31 1.01 (0.46; 2.22) 0.99 1.00 (0.44; 2.27) 1.00 Breast cancer tAML 14 4.14 (0.90; 19.04) 0.070 3.91 (0.84; 18.26) 0.083 NHL tAML 9 0.30 (0.07; 1.24) 1.10 0.29 (0.07; 1.23) 0.094 Secondary AML 64 0.99 (0.53; 1.83) 0.96 0.90 (0.47; 1.71) 0.74
STRESS MYOCARDIAL PERFUSION IMAGING IN ANOMALOUS AORTIC ORIGIN OF A CORONARY ARTERY: RESULTS FOLLOWING A STANDARDIZED APPROACH
Authors: Hitesh Agrawal, Carlos Mery, Rajesh Krishnamurthy, Kristen Sexson, Cory Noel, Prakash Masand, Siddharth Jadhav, Emmett McKenzie, Athar Qureshi, Charles Fraser, Silvana Molossi
Journal: Journal of the American College of Cardiology (2017)
Molecular cytogenetic analysis of bladder cancer by array-based comparative genomic hybridization and FISH
Authors: See-Tong Pang, Wen-Hui Weng, Kun-Lung Chuang, Phei-Lang Chang, Cheng-Keng Chuang
Journal: Clinical Cancer Research (2008)

B18  Introduction: Genetic alterations are frequently found in bladder cancer. Here we investigate the DNA copy number alterations in Taiwanese bladder cancer subpopulation using a high resolution array-based comparative genomic hybridization (CGH) technique. We also tested the diagnostic value of fluorescence in situ hybridization (FISH) in these patients using UroVysion kit.  Materials and Methods: Whole-genome analyses were performed in fifteen bladder tumors using NimbleGen microarray system. The main feature of the microarray contains 385,000 probes on a single glass slide, which tiled through genic and intergenic regions at a median probe spacing of 6,000 bp. We also examined the polyploidy of chromosome 3, 7, 17 and aneuploidy of chromosome 21 in voided or instrumental urine from these patients.  Results: We have identified several recurrent genetic changes in these bladder tumors. The most frequent changes of DNA alterations were deletion of chromosome 1q (70%), 8p (50%), 9q21 (50%), and 10q21.1-23.3 (50%). Other frequent gain were of chromosome 18q11.2-22.3 (50%) and 3. Several of these alterations were found in previous results from conventional CGH and loss of heterozygosity analyses on bladder tumors. However, the FISH detection rate for bladder tumor using UroVysion was 84%.  Conclusion: Array-CGH revealed several DNA copy number alterations that were unique in bladder cancer. These alterations will help us to identify oncogenes or tumor suppressor genes that are important in the pathophysiology of bladder cancer. UroVysion, an non-invasive cytogenetic analysis tool, is a valuable method in the diagnosis of Taiwanese patient with bladder cancer.
Abstract 35: Pseudo-knockin Mice Expressing JPH2-A399S Develop Cardiac Hypertrophy by Magnetic Resonance Imaging
Authors: Ann P Quick, David L Beavers, Jordan Showell, Leonne E Philippen, Andrew P Landstrom, Shaine A Morris, Robia G Pautler, Xander H Wehrens
Journal: Circulation Research (2015)

Background: Dysfunctional intracellular Ca2+ handling has been implicated in adverse cardiac remodeling leading to hypertrophy and failure. Recent evidence has linked mutations in the Ca2+ handling protein Junctophilin-2 (JPH2) with the development of hypertrophic cardiomyopathy (HCM). However, the mechanism remains unknown. Objective: To use advanced in vivo imaging modalities in conjunction with biochemical techniques to determine the mechanism of hypertrophic remodeling in a murine model hosting a novel JPH2 mutation. Methods and Results: 1. Pseudo-knockin (PKI) Mice: transgenic mice with the JPH2-A399S mutation (or WT JPH2) containing inducible shJPH2 were dosed with tamoxifen to knock down the combined levels of JPH2 to near WT expression. 2. MRI: A399S and WT PKI controls were imaged at 2 months post injection at which time body weight was similar for mutants (29.8±.81g) and controls (31.8±1.29g). Intragate (Bruker) was used to obtain FLASH cine images and EKG-gated tagged images were obtained to determine strain. MRI post-processing and measurements were performed using Amira and Diagnosoft software. A399S PKI mice exhibited significantly increased left ventricular mass (2.96±.21g/kg; n=4) compared to controls (2.27±.08g/kg; n=3) and max diastolic septal thickness (1.39±.05mm; n=9 versus 0.97±.00mm; n=4; P&lt;0.01). Mutants trended toward decreased septal strain (-8.97±1.04; n=4) compared to the control (-10.28; n=1) indicative of reduced regional contractility 3. Biochemistry: stress markers were measured by qPCR. Average BNP was increased over 3 fold. Larger sample size is needed to reach significance. Western blot showed no significant change (p=.78) in phosphorylated Ca2+/calmodulin-dependent protein kinase II, which is often activated by aberrant Ca2+ signaling. Conclusions: Our data show that the JPH2-A399S mutation leads to septal hypertrophy in PKI mice. This suggests that defects in JPH2 are sufficient to induce pathological cardiac remodeling. Despite the role of JPH2 in Ca2+ handling, this form of hypertrophy does not appear to be mediated by traditional Ca2+ signaling. Further studies will focus on alternative Ca2+-dependent pathways to elucidate the molecular mechanisms of these hypertrophic changes.
COMBINED MIGRAINE AND PLATYPNEA-ORTHODEOXIA SYNDROME DUE TO COMBINED ATRIAL SEPTAL DEFECT AND PATENT FORAMEN OVALE
Authors: Mohamed Teleb, Harsh Agrawal, Aymen Albaghdadi, Ahmed Ibrahim, Waseem Shami, Sarmad Said, Sucheta Gosavi, Yuefeng Chen, Wael El Mallah
Journal: Journal of the American College of Cardiology (2017)
SEASONAL VARIATION IN IN-PATIENT MORTALITY, COST OF HOSPITALIZATION AND LENGTH OF STAY IN HEART FAILURE PATIENTS IN THE UNITED STATES
Authors: Emmanuel Akintoye, Alexandros Briasoulis, Oluwole Adegbala, Muhammad Adil Sheikh, Manmohan Singh, Abdelrahman Ahmed, Diane Levine
Journal: Journal of the American College of Cardiology (2017)
ASSOCIATIONS BETWEEN EXERCISE PRIOR TO AND AROUND THE TIME OF CANCER DIAGNOSIS AND SUBSEQUENT CARDIOVASCULAR EVENTS IN WOMEN WITH BREAST CANCER: A WOMEN'S HEALTH INITIATIVE (WHI) ANALYSIS
Authors: Andres Palomo, Roberta M. Ray, Lisa Johnson, Electra Paskett, Bette Caan, Lee Jones, Tochi Okwuosa
Journal: Journal of the American College of Cardiology (2017)
Evaluation de l efficacite et de la surete de la myotomie endoscopique avec le hook knife: 135 cas
Authors: H Foisy, M Pioche, S Roman, J Rivory, F Mion, T Ponchon
Journal: Endoscopy (2017)

La myotomie endoscopique (POEM) est une nouvelle procédure non invasive prometteuse pour le traitement de l'achalasie de l'oesophage. La technique doit être très précise et le Hook knife peut être utilisé pour la réalisation de la myotomie. Nous avons évalué les résultats de cette technique pour les 135 premiers patients de notre centre.
Update of melphalan 280 mg/m<sup>2 </sup>plus amifostine cytoprotection before autologous stem cell transplantation as part of initial therapy in multiple myeloma patients
Authors: D. E. Reece, N. Flomenberg, A. Badros, G. L. Phillips, J. Filicko, D. S. Howard, B. Meisenberg, A. Rapoport, D. H. Vesole
Journal: Journal of Clinical Oncology (2006)

7608 Background: Autologous stem cell transplantation (ASCT) using melphalan 200 mg/m 2 is a standard part of inital therapy in younger multiple myeloma (MM) patients (pts). We have previously reported an augmented regimen of melphalan 280 mg/m 2 with the cytoprotectant agent amifostine (AF) to try to improve the anti-tumor response without increased mucosal toxicity (The Hematol J 2003; 4[suppl]: S207). We now update our experience with this regimen. Methods: Pts without disease progression and adequate organ function (creatinine clearance at least 60 cc/min) were eligible. Pts were treated as part of phase I-II trials approved by each center’s institutional review board. AF 740 mg/m 2 was given IV over 5–15 min 24 hr and 15 min prior to melphalan 280 mg/m 2 (infused over 15 min). Blood stem cells were reinfused 24 hrs later. The primary endpoint was response rate at day 100. Regimen-related toxicity using the Seattle criteria, progression-free (PFS) and overall survival (OS) were also assessed. Results: 24 pts were transplanted between 5/99–7/02. Median age was 50 (32–65) yrs; 1 pt had primary amyloidosis; median beta2-microglobulin level at diagnosis was 1.98 (0.88–11.80) mg/L. Prior therapy included VAD in 14, dexamethasone alone in 7 plus other regimens in 7. Day 100 responses compared with with pre-ASCT values included CR in 11, near CR (immunofixation positivity only) in 1, VGPR (greater than 90% reduction in serum M protein) in 3, PR in 5 and stable disease in 3. Maximum grade of mucositis was 2 (5 pts); no grade 3 or 4 toxicity was seen. The median day of ANC recovery to 0.5 x 10 9 /L and median day of last platelet transfusion were 11 (6–16) and 10 (7–32), respectively. 4 received thalidomide (1 briefly), while 1 was treated with maintenance alpha interferon after day 100. Median follow-up is 52 (9–72) mos. 7 pts are alive without progression, including 5 in CR and 2 in PR. 16 have progressed at a median of 15 (7–36) mos post-ASCT. 8 have died from MM (7) or lung cancer (1). The 4 yr actuarial PFS is 28% (95% C.I. 34–76%) and OS 58% (95% C.I.11–47%). Conclusions: 1) Melphalan 280 mg/m 2 with AF is well-tolerated; 2) the CR + nCR + VGPR rate of 62% warrants further evaluation, perhaps as part of tandem transplants or in conjuction with novel agents. [Table: see text]